NCT06961669View on ClinicalTrials.gov

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

NARecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)
Interventions
DRUG

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis

A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 1.0-5.0 x10\^5 CART cells/kg）.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV